In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

This reference details recent knowledge of ovarian cancer. Areas covered include: the genetic basis and molecular biology of ovarian cancer, analytic approaches to diagnosis and management, experimental therapeutics - gene therapy, methodology for dose intensification, new drugs, and quality of life and ethical issues.

"Featuring more than 300 illustrations, the text covers pathology, biology, epidemiology, genetics, and screening through surgical management, the latest in chemotherapeutic regimens, and finally, palliative care"--P. [4] of cover.

Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.

Each year, about 22,000 women will be diagnosed with ovarian cancer, and more than 14,000 women will die from it. This essential guidebook provides information on Ovarian Cancer, but also serves as a historical survey, by providing information on the controversies surrounding its causes, and first-person narratives by people coping with Ovarian Cancer. Readers will learn from the words of patients, family members, or caregivers. The symptoms, causes, treatments, and potential cures are explained in detail. Alternative treatments are also covered. Student researchers and readers will find this book easily accessible through its careful and conscientious editing and a thorough introduction to each essay. Includes charts, graphs, and tables.

This book is a printed edition of the Special Issue "The Tumor Microenvironment of High Grade Serous Ovarian Cancer" that was published in Cancers

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. - Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response - Discusses genetic reversions as a unique alteration and a new field of study - Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

"Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this book offers help. Completely revised and updated ... [this book] gives authoritative, practical answers to questions about treatment options."--Page [4] cover.